BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 20573459)

  • 1. Primary cutaneous blastic plasmacytoid dendritic cell neoplasm without extracutaneous manifestation: case report and review of the literature.
    Li Y; Li Z; Lin HL; Chen XH; Li B
    Pathol Res Pract; 2011 Jan; 207(1):55-9. PubMed ID: 20573459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of CD4+/CD56+ hematodermic neoplasm (plasmacytoid dendritic cell neoplasm).
    Su O; Onsun N; Demirkesen C; Aydin Y; Pirmit S; Gereli M
    Dermatol Online J; 2010 Apr; 16(4):8. PubMed ID: 20409415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4+/CD56+ Hematodermic neoplasm (plasmacytoid dendritic cell tumor).
    Shiman M; Marchione R; Ricotti C; Romanelli P; Alonso-Llamazares J
    Dermatol Online J; 2008 Nov; 14(11):5. PubMed ID: 19094843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Sustained remission of blastic plasmacytoid dendritic cell neoplasm with ABVD chemotherapy].
    Tanikawa S; Sakuranaka H; Chong JM; Okada Y; Takimoto M
    Rinsho Ketsueki; 2012 Feb; 53(2):246-51. PubMed ID: 22450587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4+/CD56+ hematodermic neoplasm: report of a rare variant with a T-cell receptor gene rearrangement.
    Stetsenko GY; McFarlane R; Kalus A; Olerud J; Cherian S; Fromm J; George E; Argenyi Z
    J Cutan Pathol; 2008 Jun; 35(6):579-84. PubMed ID: 18005171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimen.
    Shapiro M; Wasik MA; Junkins-Hopkins JM; Rook AH; Vittorio CC; Itakura H; Frankel MC; Georgala S; Schuster SJ
    Am J Hematol; 2003 Sep; 74(1):46-51. PubMed ID: 12949889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An unusual case of cutaneous blastic plasmacytoid dendritic cell neoplasm with concomitant B-cell lymphoproliferative disorder.
    Patel JL; Shetty S; Salama ME
    Am J Dermatopathol; 2011 May; 33(3):e31-6. PubMed ID: 20861710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+ CD56+ blastic tumor of the skin: cytogenetic observations and further evidence of an origin from plasmocytoid dendritic cells.
    Hallermann C; Middel P; Griesinger F; Gunawan B; Bertsch HP; Neumann C
    Eur J Dermatol; 2004; 14(5):317-22. PubMed ID: 15358570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blastic plasmacytoid dendritic cell neoplasm without cutaneous lesion at presentation: case report and literature review.
    Wang H; Cao J; Hong X
    Acta Haematol; 2012; 127(2):124-7. PubMed ID: 22236870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Blastic plasmacytoid dendritic cell neoplasm - a rare differential diagnosis of neoplastic skin infiltrations associated with systemic symptoms].
    Löffler H; Kosely F; Ho AD; Krämer A
    Dtsch Med Wochenschr; 2009 Sep; 134(39):1927-30. PubMed ID: 19760552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Childhood CD4+/CD56+ hematodermic neoplasm: case report and review of the literature.
    Ruggiero A; Maurizi P; Larocca LM; Arlotta A; Riccardi R
    Haematologica; 2006 Dec; 91(12 Suppl):ECR48. PubMed ID: 17194654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate.
    Leitenberger JJ; Berthelot CN; Polder KD; Pro B; McLaughlin P; Jones D; Duvic M
    J Am Acad Dermatol; 2008 Mar; 58(3):480-4. PubMed ID: 18280345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD56+ lymphoma with skin involvement: clinicopathologic features and classification.
    Gniadecki R; Rossen K; Ralfkier E; Thomsen K; Skovgaard GL; Jønsson V
    Arch Dermatol; 2004 Apr; 140(4):427-36. PubMed ID: 15096371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lacking CD56 expression in a relapsing cutaneous blastic plasmacytoid dendritic cell neoplasm after allogeneic bone marrow transplantation: FISH analysis revealed loss of 11q.
    Mitteldorf C; Bertsch HP; Baumgart M; Haase D; Wulf G; Schön MP; Rosenwald A; Neumann C; Kaune KM
    J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1225-9. PubMed ID: 21923812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary cutaneous small/medium CD4+ T-cell lymphomas: a heterogeneous group of tumors with different clinicopathologic features and outcome.
    Garcia-Herrera A; Colomo L; Camós M; Carreras J; Balague O; Martinez A; Lopéz-Guillermo A; Estrach T; Campo E
    J Clin Oncol; 2008 Jul; 26(20):3364-71. PubMed ID: 18541895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
    Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
    Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An atypical presentation of a blastic plasmacytoid dendritic cell tumors.
    López V; Martí N; Ferrández A; Martin JM; Jordá E
    J Cutan Pathol; 2010 Sep; 37(9):e50-2. PubMed ID: 19615025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological features and prognostic significance of CXCL12 in blastic plasmacytoid dendritic cell neoplasm.
    Hashikawa K; Niino D; Yasumoto S; Nakama T; Kiyasu J; Sato K; Kimura Y; Takeuchi M; Sugita Y; Hashimoto T; Ohshima K
    J Am Acad Dermatol; 2012 Feb; 66(2):278-91. PubMed ID: 21835496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary cutaneous Epstein-Barr virus-associated T-cell lymphoproliferative disorder-2 cases with unusual, prolonged clinical course.
    Park S; Lee DY; Kim WS; Ko YH
    Am J Dermatopathol; 2010 Dec; 32(8):832-6. PubMed ID: 20595887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
    Weiser MA; O'Brien S; Thomas DA; Pierce SA; Lam TP; Kantarjian HM
    Cancer; 2002 Jan; 94(2):285-91. PubMed ID: 11900213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.